Janssen Pharmaceutica, Inc. v. Bailey

Summary

The Supreme Court of Mississippi reviewed a products-liability action involving alleged injuries from the prescription medication Propulsid. The plaintiffs asserted failure-to-warn and negligent-misrepresentation claims, and a jury awarded substantial compensatory damages that were reduced by remittitur. Relying on its recent decision in Janssen Pharmaceutica, Inc. v. Armond, the court addressed the appropriate disposition of the appeal.

Holdings

1. Joinder of the ten plaintiffs was improper because their claims arose from individual facts and circumstances rather than the same transaction, occurrence, or series of transactions or occurrences, and the joint trial unfairly prejudiced the defendants.
2. The trial court abused its discretion by transferring the case from Jefferson County to neighboring Claiborne County, because the record showed that Claiborne County was not sufficiently free from bias and community connections to permit a fair trial.
3. The trial court abused its discretion by denying a new trial because the plaintiffs' medical evidence did not adequately account for substantial preexisting conditions and alternative causes, and the verdict was against the overwhelming weight of the evidence.
4. The adequacy of Janssen's warnings was a question of fact for the jury, but the plaintiffs still bore the burden of proving that Propulsid caused their injuries and that an adequate warning would have altered the prescribing physicians' decisions.
5. The trial court did not err by submitting Johnson & Johnson's direct liability to the jury because the evidence permitted a finding that it actively participated in the marketing and plan for Propulsid.

Questions Presented

1. Whether the ten plaintiffs were improperly joined under Mississippi Rule of Civil Procedure 20 because their claims did not arise from the same transaction or occurrence.
2. Whether the trial court abused its discretion by transferring venue from Jefferson County to Claiborne County despite evidence of community bias and connections to Propulsid litigation.
3. Whether the plaintiffs presented sufficient evidence of medical causation to support the verdict and whether denial of a new trial was an abuse of discretion.
4. Whether the FDA-approved warnings were adequate as a matter of law or whether adequacy remained a factual question for the jury.
5. Whether the trial court improperly permitted inflammatory closing argument concerning dismissed misrepresentation claims and punitive damages.
6. Whether sufficient evidence supported submitting Johnson & Johnson's direct liability to the jury.

Disposition

reversed_and_remanded